139 related articles for article (PubMed ID: 36752488)
1. Augmentation of Natriuretic Peptide Bioactivity via Combined Inhibition of Neprilysin and Phosphodiesterase-9 in Heart Failure.
Scott NJA; Prickett TCR; Charles CJ; Frampton CM; Richards AM; Rademaker MT
JACC Heart Fail; 2023 Feb; 11(2):227-239. PubMed ID: 36752488
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic, Hormonal, and Renal Actions of Phosphodiesterase-9 Inhibition in Experimental Heart Failure.
Scott NJA; Rademaker MT; Charles CJ; Espiner EA; Richards AM
J Am Coll Cardiol; 2019 Aug; 74(7):889-901. PubMed ID: 31416533
[TBL] [Abstract][Full Text] [Related]
3. Combined Inhibition of Phosphodiesterase-5 and -9 in Experimental Heart Failure.
Rademaker MT; Scott NJA; Charles CJ; Richards AM
JACC Heart Fail; 2024 Jan; 12(1):100-113. PubMed ID: 37921801
[TBL] [Abstract][Full Text] [Related]
4. CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload-Induced Heart Failure.
Richards DA; Aronovitz MJ; Liu P; Martin GL; Tam K; Pande S; Karas RH; Bloomfield DM; Mendelsohn ME; Blanton RM
Circ Heart Fail; 2021 Jan; 14(1):e007300. PubMed ID: 33464954
[TBL] [Abstract][Full Text] [Related]
5. Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure.
Rademaker MT; Charles CJ; Cooper GJ; Coy DH; Espiner EA; Lewis LK; Nicholls MG; Richards AM
Hypertension; 2002 Jan; 39(1):93-8. PubMed ID: 11799085
[TBL] [Abstract][Full Text] [Related]
6. Natriuretic peptide analogues with distinct vasodilatory or renal activity: integrated effects in health and experimental heart failure.
Rademaker MT; Scott NJA; Koh CY; Kini RM; Richards AM
Cardiovasc Res; 2021 Jan; 117(2):508-519. PubMed ID: 32167565
[TBL] [Abstract][Full Text] [Related]
7. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure.
Rademaker MT; Charles CJ; Kosoglou T; Protter AA; Espiner EA; Nicholls MG; Richards AM
Am J Physiol; 1997 Nov; 273(5):H2372-9. PubMed ID: 9374774
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway.
Yamamoto T; Wada A; Tsutamoto T; Ohnishi M; Horie M
J Cardiovasc Pharmacol; 2004 Nov; 44(5):596-600. PubMed ID: 15505498
[TBL] [Abstract][Full Text] [Related]
9. Comparison of chronic neutral endopeptidase inhibition and furosemide in an ovine model of heart failure.
Rademaker MT; Fitzpatrick MA; Charles CJ; Richards AM; Nicholls MG; Espiner EA; Sybertz E
J Cardiovasc Pharmacol; 1996 Mar; 27(3):439-46. PubMed ID: 8907807
[TBL] [Abstract][Full Text] [Related]
10. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure.
Rademaker MT; Charles CJ; Espiner EA; Nicholls MG; Richards AM; Kosoglou T
Clin Sci (Lond); 1996 Sep; 91(3):283-91. PubMed ID: 8869410
[TBL] [Abstract][Full Text] [Related]
11. Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease.
Chen Y; Burnett JC
Clin Chem; 2017 Jan; 63(1):108-115. PubMed ID: 28062615
[TBL] [Abstract][Full Text] [Related]
12. Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions.
Bozkurt B; Nair AP; Misra A; Scott CZ; Mahar JH; Fedson S
JACC Basic Transl Sci; 2023 Jan; 8(1):88-105. PubMed ID: 36777165
[TBL] [Abstract][Full Text] [Related]
13. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment.
Lainchbury JG; Richards AM; Nicholls MG; Espiner EA; Yandle TG
J Clin Endocrinol Metab; 1999 Feb; 84(2):723-9. PubMed ID: 10022444
[TBL] [Abstract][Full Text] [Related]
14. Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.
Wegner M; Ganten D; Stasch JP
Hypertens Res; 1996 Dec; 19(4):229-38. PubMed ID: 8986453
[TBL] [Abstract][Full Text] [Related]
15. Enhanced natriuretic response to neutral endopeptidase inhibition in heart-transplant recipients.
Geny B; Hardy H; Lonsdorfer J; Eisenmann B; Haberey P; Piquard F
Hypertension; 1999 Apr; 33(4):969-74. PubMed ID: 10205232
[TBL] [Abstract][Full Text] [Related]
16. Acute hemodynamic, hormonal, and renal effects of neutral endopeptidase inhibition in ovine heart failure.
Fitzpatrick MA; Rademaker MT; Charles CJ; Yandle TG; Espiner EA; Ikram H; Sybertz E
J Cardiovasc Pharmacol; 1992 Apr; 19(4):635-40. PubMed ID: 1380608
[TBL] [Abstract][Full Text] [Related]
17. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.
Martin FL; Stevens TL; Cataliotti A; Schirger JA; Borgeson DD; Redfield MM; Luchner A; Burnett JC
Kidney Int; 2005 May; 67(5):1723-30. PubMed ID: 15840018
[TBL] [Abstract][Full Text] [Related]
18. CRRL269: a novel designer and renal-enhancing pGC-A peptide activator.
Chen Y; Harty GJ; Huntley BK; Iyer SR; Heublein DM; Harders GE; Meems L; Pan S; Sangaralingham SJ; Ichiki T; Burnett JC
Am J Physiol Regul Integr Comp Physiol; 2018 Mar; 314(3):R407-R414. PubMed ID: 29187381
[TBL] [Abstract][Full Text] [Related]
19. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II.
Rademaker MT; Charles CJ; Espiner EA; Nicholls MG; Richards AM; Kosoglou T
J Cardiovasc Pharmacol; 1998 Jan; 31(1):116-25. PubMed ID: 9456286
[TBL] [Abstract][Full Text] [Related]
20. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
Forfia PR; Lee M; Tunin RS; Mahmud M; Champion HC; Kass DA
J Am Coll Cardiol; 2007 Mar; 49(10):1079-88. PubMed ID: 17349888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
